Parathyroid Disease Treatment Market Report 2026

Parathyroid Disease Treatment Market Overview

• Parathyroid Disease Treatment market size has reached to $2.37 billion in 2025 • Expected to grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Rising Prevalence Of Chronic Kidney Disease (CKD) Driving The Market Growth Due To Increasing Risk Of Secondary Hyperparathyroidism • Market Trend: Advancing Hormone Replacement Therapies For Better Outcomes • Asia-Pacific was the largest region in 2025.

What Is Covered Under Parathyroid Disease Treatment Market?

Parathyroid disease treatment refers to the medical and surgical interventions used to manage disorders affecting the parathyroid glands, which are small endocrine glands located in the neck that regulate calcium and phosphorus levels in the body through the secretion of parathyroid hormone (PTH). The main types of parathyroid disease treatment include calcimimetics, bisphosphonates, plicamycin, hormone replacement therapy, and other treatments. Calcimimetics are drugs that reduce parathyroid hormone (PTH) levels by mimicking calcium and activating calcium-sensing receptors on the parathyroid glands. These drugs are administered through various routes, such as oral and parenteral, distributed via hospital pharmacies, online pharmacies, and retail pharmacies, and used by various end-users, including hospitals, homecare settings, specialty centers, and others.

What Is The Parathyroid Disease Treatment Market Growth Forecast?

The parathyroid disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for calcimimetics and bisphosphonates, advancements in parathyroid imaging and diagnostics, growing homecare and telemedicine solutions, regulatory support for precision medicine, expanding specialty centers for endocrine disorders. Major trends in the forecast period include increasing adoption of calcimimetics and bisphosphonates, rising preference for parenteral over oral administration in severe cases, expansion of hospital and specialty care settings, growing focus on personalized hormone replacement therapies, integration of lifestyle and nutritional interventions in treatment plans.

Global Parathyroid Disease Treatment Market Segmentation

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments 2) By Route Of Administration: Oral, Parenteral 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Calcimimetics: Cinacalcet, Etelcalcetide 2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid 3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin 4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs) 5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

What Is The Driver Of The Parathyroid Disease Treatment Market?

The rising prevalence of chronic kidney disease (CKD) is expected to propel the growth of the parathyroid disease treatment market going forward. Chronic kidney disease is a long-term condition where the kidneys gradually lose function, leading to imbalances in minerals such as calcium and phosphorus. The rising prevalence of chronic kidney disease (CKD) is primarily due to the increasing incidence of diabetes, as persistently high blood sugar levels can damage the kidneys' filtering units over time, leading to diabetic nephropathy. Parathyroid disease treatment is essential in managing chronic kidney disease (CKD) by targeting secondary hyperparathyroidism, a frequent complication in advanced CKD that disrupts calcium and phosphorus balance, contributes to bone disease, and promotes vascular calcification. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, more than one in seven adults in the US which is about 35.5 million people or roughly 14% were estimated to have chronic kidney disease in 2023, and nearly 90% of those affected were unaware of their condition. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the parathyroid disease treatment industry.

Key Players In The Global Parathyroid Disease Treatment Market

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.

Global Parathyroid Disease Treatment Market Trends and Insights

Major companies operating in the parathyroid disease treatment market are focusing on the development of innovative products such as parathyroid hormone prodrugs to improve calcium regulation and reduce dosing frequency in patients with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that convert into active PTH in the body to regulate calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone (PTH[1-34]) for the treatment of chronic hypoparathyroidism in adults. This once-daily therapy provides continuous parathyroid hormone exposure over 24 hours, offering an alternative to conventional calcium and vitamin D supplementation by directly addressing the underlying hormone deficiency. The approval of YORVIPATH underscores the increasing emphasis on advanced hormone replacement therapies aimed at enhancing treatment adherence and delivering better clinical outcomes for patients with parathyroid disorders.

What Are Latest Mergers And Acquisitions In The Parathyroid Disease Treatment Market?

In July 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Amolyt Pharma SAS for $1.05 billion. With this acquisition, AstraZeneca PLC aims to strengthen its Alexion Rare Disease portfolio by advancing its late-stage pipeline and expanding its bone metabolism franchise through the addition of eneboparatide (AZP-3601), a Phase III investigational therapy designed to treat hypoparathyroidism. Amolyt Pharma SAS is a France-based clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases, including parathyroid disorders such as hypoparathyroidism.

Regional Insights

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Parathyroid Disease Treatment Market?

The parathyroid disease treatment market consists of revenues earned by entities by providing services such as diagnostic testing, surgical intervention, hormone level monitoring, post-operative care, and medical management of calcium and phosphate balance. The market value includes the value of related goods sold by the service provider or included within the service offering. The parathyroid disease treatment market also includes sales of lanthanum carbonate, doxercalciferol, calcitriol, lanthanum carbonate, and parsabiv. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Parathyroid Disease Treatment Market Report 2026?

The parathyroid disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.